Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Herbert J. Zeh, Shikhar Uttam, Alessandro Paniccia, Melissa E. Hogg, Kevin McGrath, Adam Slivka, Vikram C. Gorantla, Rohit Das, Katelyn Smith, Roby Antony Thomas, Asif Khalid, Michael S. Landau, Kenneth E. Fasanella, Natalie Seiser, James F. Pingpank, Harkirat Singh, Nathan Bahary, Patrick Henn, Kenneth K. Lee, Brian K. Theisen, Melanie Ongchin, Savreet Sarkaria, Randall E. Brand, Aatur D. Singhi, Brian A. Boone, Amer H. Zureikat, Susannah G. Ellsworth, N. Paul Ohori, Anil K. Dasyam, Jennifer Chennat, Susan Shyu, John C. Rhee
Publikováno v:
Clin Gastroenterol Hepatol
BACKGROUND & AIMS: The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing current gradi
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Sidrah Khan, Caroline J. Rieser, Richard S. Hoehn, Samer Tohme, Ibrahim Nassour, David S. Medich, Amer H. Zureikat, Lindsay M. Sabik, Katherine Hrebinko
Publikováno v:
J Surg Res
Background Safety-net hospitals serve a vital role in society by providing care for vulnerable populations. Existing data regarding oncologic outcomes of patients with colon cancer treated at safety-net hospitals are limited and variable. The objecti
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Melissa E. Hogg, Sarwat B. Ahmad, Ahmad Hamad, Amer H. Zureikat, T. Peter Kingham, Jin He, Mary Joe K. Rice, Herbert J. Zeh, Cecilia Chang, Jose M. Pimiento
Publikováno v:
Ann Surg Oncol
PURPOSE: To implement a mastery-based robotic surgery curriculum using virtual reality (VR) and inanimate reality (IR) drills at multiple Complex General Surgical Oncology (CGSO) fellowships. METHODS: A prospective study of curriculum feasibility and
Autor:
Ibrahim Nassour, Kenneth K. Lee, Samer Tohme, Christof Kaltenmeier, Sidrah Khan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Richard S. Hoehn, Katherine Hrebinko
Publikováno v:
Pancreas
Objectives The objective of this study was to create a composite measure, optimal oncologic surgery (OOS), for patients undergoing distal pancreatectomy for pancreatic adenocarcinoma and identify factors associated with OOS. Methods Adult patients un
Autor:
Asif Khalid, Nathan Bahary, Sharon Winters, Lauren Stitt, Adam C. Olson, Richard S. Hoehn, Adam Slivka, Kenneth K. Lee, Ritu Sarkaria, James Ohr, Caroline J. Rieser, Randal E. Brand, Steve Burton, Vikram C. Gorantla, David L. Bartlett, Kenneth E. Fasanella, Jennifer Chennat, Rohit Das, Aatur D. Singhi, Herbert J. Zeh, Anuradha Krishnamurthy, Melissa E. Hogg, John C. Rhee, Susannah G. Ellsworth, Kevin McGrath, Alessandro Paniccia, Amer H. Zureikat
Publikováno v:
Ann Surg Oncol
AIMS: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on
Autor:
Amer H. Zureikat, Daniel Barnett, Ying Huang, Mirna Kheir Gouda, Luke Wisniewski, Douglas B. Evans, Ben Staal, Chong-Feng Gao, Peter J. Allen, Dennis Plenker, Aatur D. Singhi, Randall E. Brand, Ying Liu, David A. Tuveson, Susan Tsai, Ian Beddows, Mohammed Aldakkak, Brian B. Haab, Johnathan Hall, Richard R. Drake
Publikováno v:
Clin Cancer Res
Purpose:A subset of pancreatic ductal adenocarcinomas (PDACs) is highly resistant to systemic chemotherapy, but no markers are available in clinical settings to identify this subset. We hypothesized that a glycan biomarker for PDACs called sialylated
Autor:
M.E. Hogg, Brian A. Boone, Kenneth K. Lee, Alessandro Paniccia, Nathan Bahary, Susannah G. Ellsworth, Amer H. Zureikat, Joal D. Beane, David L. Bartlett, Asmita Chopra, Michael T. Lotze, Aatur D. Singhi, Herbert J. Zeh, Adam C. Olson, Jacob C. Hodges, Steve Burton
Publikováno v:
Ann Surg Oncol
BACKGROUND. Neoadjuvant therapy is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC). It is unknown whether neoadjuvant chemoradiotherapy is more effective than chemotherapy (NCRT vs. NAC). We aim to compare pathological and